Advertisement Datafarm's Daniel Orfe to present at the DIA 8th Annual Electronic Submissions Conference - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

eSubmissions Made Easy

More info about

Datafarm’s Daniel Orfe to present at the DIA 8th Annual Electronic Submissions Conference

18 Nov, 2009 – Datafarm Inc., a world leading provider of high performance
electronic regulatory submission solutions for the Life Sciences industry, is pleased to announced that Mr
Daniel F Orfe, vice president of Global Regulatory Submission Services at Datafarm, will present within the
Changing Your Business Model To Get The Most Out Of Your eCTD session at the Drug Information
Association’s (DIA’s) 8th Annual Electronic Submissions Conference; eCTD: The Adventure Continues to
be held on November 17-19, 2009 at the Westin in San Diego, CA.

The DIA 8th Annual Electronic Submissions Conference; eCTD: The Adventure Continues will discuss
current developments in eCTD in the US and Europe, filing CTD formatted submissions in other markets,
and emerging technologies having an impact on electronic submissions.

Mr Orfe’s presentation within the session is entitled Producing and Delivering eCTDs: Considerations
When Deciding In-house Staff, Outsource Partner or Both. The session is scheduled for Wednesday,
November 18th at 3:30pm. “As the eCTD gains global momentum, decision making on how to best
accomplish producing eCTDs is difficult for many companies. Companies can achieve significant
advantages by adopting the eCTD however they also face challenges to effect their transition,” said Mr.
Orfe. “I look forward to outlining items sponsor companies should consider to facilitate making the decision
which best meets their specific business needs,” concluded Mr Orfe.

About the Drug Information Association (DIA)

DIA serves more than 30,000 biopharmaceutical professionals from industry, academia, and regulatory
agencies worldwide. Through its domestic and international meetings, training courses, workshops and
webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of
the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with
offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its
volunteer-based Board of Directors and executive management team. For more information, visit
www.diahome.org or call 215-442-6100.